BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 927 filers reported holding BAXTER INTL INC in Q4 2016. The put-call ratio across all filers is 0.70 and the average weighting 0.3%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $620,000 | -90.4% | 11,509 | -88.6% | 0.02% | -91.2% |
| Q2 2022 | $6,458,000 | +123.5% | 100,550 | +169.8% | 0.24% | +140.4% |
| Q1 2022 | $2,890,000 | +69.1% | 37,271 | +87.3% | 0.10% | +67.8% |
| Q4 2021 | $1,709,000 | -73.9% | 19,900 | -75.6% | 0.06% | -72.3% |
| Q3 2021 | $6,554,000 | +121.8% | 81,482 | +121.9% | 0.21% | +121.9% |
| Q2 2021 | $2,955,000 | +10453.6% | 36,712 | +10826.2% | 0.10% | +9500.0% |
| Q1 2021 | $28,000 | -96.8% | 336 | -96.9% | 0.00% | -97.5% |
| Q4 2020 | $883,000 | -80.8% | 11,000 | -80.7% | 0.04% | -91.8% |
| Q3 2020 | $4,589,000 | +26894.1% | 57,062 | +21931.7% | 0.49% | +5987.5% |
| Q4 2018 | $17,000 | -86.1% | 259 | -83.6% | 0.01% | -81.0% |
| Q3 2018 | $122,000 | -86.4% | 1,578 | -88.6% | 0.04% | -90.9% |
| Q1 2018 | $897,000 | +209.3% | 13,797 | +207.6% | 0.46% | +108.1% |
| Q4 2017 | $290,000 | +111.7% | 4,485 | +104.8% | 0.22% | +128.9% |
| Q3 2017 | $137,000 | -5.5% | 2,190 | -32.9% | 0.10% | -33.1% |
| Q4 2016 | $145,000 | -78.2% | 3,262 | -76.7% | 0.14% | -60.1% |
| Q3 2016 | $666,000 | +1652.6% | 14,000 | +1300.0% | 0.36% | +188.1% |
| Q4 2015 | $38,000 | -89.2% | 1,000 | -79.6% | 0.13% | -35.1% |
| Q3 2014 | $351,000 | – | 4,896 | – | 0.19% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
| BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
| Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
| Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
| Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
| SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
| Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
| Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
| Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |